Navigation Links
Katherine Baicker Elected to Lilly Board of Directors
Date:12/12/2011

INDIANAPOLIS, Dec. 12, 2011 /PRNewswire/ -- Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Katherine Baicker, Ph.D. as a new member, effective December 12, 2011. Baicker, 40, is Professor of Health Economics in the Department of Health Policy and Management at the Harvard School of Public Health. She is also a research associate at the National Bureau of Economic Research and an elected member of the Institute of Medicine. As a member of Lilly's board, Professor Baicker will serve on the public policy and compliance committee. She will serve under interim election and will stand for election by Lilly shareholders at the company's annual meeting in April, 2012.

"I am very pleased to welcome Kate Baicker to the Lilly board. Her experience and expertise will surely benefit Lilly shareholders and the patients we serve," commented John Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Kate is a leading researcher in the fields of health economics, public economics and labor economics. As a valued advisor to numerous healthcare-related commissions and committees, her expertise in healthcare policy and healthcare delivery is recognized by both academia and government. In a rapidly-changing healthcare landscape, Kate's insights will be invaluable as we work to sustain an environment that is conducive to medical innovation while still ensuring access to affordable, quality healthcare."

Professor Baicker's research focuses primarily on the factors that drive the distribution, generosity, and effectiveness of public and private health insurance, with a particular focus on health insurance finance and the effect of reforms on the distribution and quality of care.  Her research has been published in journals such as Health Affairs, the Journal of Public Economics, and the Quarterly Journal of Economics, and has been featured in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 ... reports analyzing tumor biomarker tests, imaging, endoscopy ... for the global industry by technology and ... Industry (Tumor Biomarker Tests, Imaging, Endoscopy and ... talking about 9 companies and supported with ...
(Date:7/29/2015)... OSAKA, Japan , ... -- ... confirmed,   including Core ... EPS    ... Underlying revenue +6.1% year-to-year (reported revenue growing +8.5% to 446.3 billion yen) ...
(Date:7/29/2015)... Ill. , July 30, 2015  Astellas ... ACTIVE study evaluating the efficacy and safety of ... CRESEMBA® (isavuconazonium sulfate), under development for adults with ... Results from the study demonstrated that the trial ... in overall treatment response in isavuconazole-treated patients at ...
Breaking Medicine Technology:Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... Dec. 8 Cell Therapeutics, Inc. (CTI),(Nasdaq ... follow-up data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line ... of Hematology (ASH) 50th Annual Meeting by,Morschhauser, ... progression-free,survival (PFS) following Zevalin consolidation therapy for ...
... 7 Millennium: The Takeda Oncology,Company today ... randomized, multi-center,Company-sponsored Phase I/II study of VELCADE, ... previously untreated multiple,myeloma (MM). The preliminary analysis ... of four drugs was generally well tolerated ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6
(Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility ... effort to provide comfort to patients as well as visiting friends and family during ... phone charging stations. , The stations - powered by ChargeItSpot , a Philadelphia-based ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s ... and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate ... collaboration, OncLive’s editorial and marketing groups will help spread the news about the ...
(Date:7/30/2015)... ... , ... Zejax is a New Way of Training Without ... , World renown body weight trainer, Paul Ziachik, announces today that he is ... person’s training capability. , The American College of Sports Medicine states that among ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... country Myanmar did not give him more than six months ... life in a Delhi hospital which successfully conducted a live ... 10-hour liver transplant surgery at the Sir Ganga Ram Hospital, ... ago and is now getting ready to return home. ...
... care of patients of Scotland hospitals causing an imbalance in ... official watchdog to ensure //that the standards of effective dietary ... Audit report 50% of the hospitals have not yet analyzed ... who are in a critical condition and any miscalculation in ...
... their hearts face risks. The devices called stents.Stents are used ... passage of// blood. It is inserted into cardiac arteries by ... with drugs are more liable to suffer from internal blood ... compared to patients who use stents that are not medicated. ...
... research keenly studied the effect of discontinuing HIV drug therapy ... can be positively// devastating, reported the study. New England Journal ... in its Nov 30 issue. If the treatment is discontinued, ... AIDS and also suffer from toxic side effects of the ...
... used drugs that are used in treatment of cancer, ... by a research, published by the Journal of Biology.// ... brain damage. The effects may be long lasting. This ... refers to the side effects that are seen in ...
... consume junk food which is over laden with salt especially ... This has resulted in// a difficulty for them to consume ... are used to high salt intake. ,Disasters like ... which ruin the lives of many and can be corrected ...
Cached Medicine News:Health News:Myanmar National Undergoes Successful Liver Transplantation in Delhi 2Health News:Hospital Food Needs Improvement to Meet the Nutritional Needs of the Patient 2Health News:Using Heart Stents Tends to Form More Clots 2Health News:Interrupted Treatment Dangerous to HIV Management 2
... includes: Mx3005P instrument and custom filter ... (5) filters. The standard filter set ... (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) ... computer, Mx3005P analysis software, Beacon Designer ...
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... Time Thermal Block and its operation ... as quantification of gene expression, genotyping, ... validation of microarray results. Exicycler is ... two molecules, such as protein-protein and ...
Medicine Products: